EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib

Ivo N SahBandar, Chandler B Sy, Tayler van den Akker, David Kim, Julia T Geyer, Amy Chadburn, Ethel Cesarman, Giorgio Inghirami, John N Allan, Momin T Siddiqui, Madhu M Ouseph

Pathobiology · 2023

DOI: 10.1159/000530429 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pathobiology, 2023. Verfasst von Ivo N SahBandar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA, ins4002@nyp.org. Hauptthemen laut MEDLINE: Lymphoma, Primary Effusion, Sarcoma, Kaposi, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Herpesvirus 8, Human. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Primary effusion lymphoma (PEL) is a malignant lymphomatous effusion, which by definition is Kaposi sarcoma herpesvirus/human herpesvirus 8-positive. PEL typically occurs in HIV-infected patients but can also occur in HIV-negative individuals, including in organ transplant recipients. Tyrosine kinase inhibitors (TKIs) are currently the standard of care for patients with chronic myeloid leukemia (CML), BCR::ABL1-positive. Although TKIs are extremely effective in treating CML, they alter T-cell function by inhibiting peripheral T-cell migration and altering T-cell trafficking and have been associated with the development of pleural effusions. Case Presentation: We report a case of PEL in a young, relatively immunocompetent patient with no history of organ transplant receiving dasatinib for CML, BCR::ABL1-positive.

Discussion

We hypothesize that the loss of T-cell function secondary to TKI therapy (dasatinib) may have resulted in the unchecked cellular proliferation of Kaposi sarcoma herpesvirus (KSHV)-infected cells, leading to the emergence of a PEL. We recommend cytologic investigation and KSHV testing in patients being treated with dasatinib for CML who present with persistent or recurrent effusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Primary EffusionSarcoma, KaposiLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHerpesvirus 8, HumanHIV InfectionsHumansDasatinib

Stichwörter der Autor:innen

Chronic myeloid leukemiaDasatinibLymphomaPrimary effusion lymphoma

Substanzen

Dasatinib

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA, ins4002@nyp.org.
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.

Zitieren

APA

SahBandar, I. N., Sy, C. B., van den Akker, T., Kim, D., Geyer, J. T., Chadburn, A., Cesarman, E., Inghirami, G., Allan, J. N., Siddiqui, M. T., & Ouseph, M. M. (2023). Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib. Pathobiology. https://doi.org/10.1159/000530429

Vancouver

SahBandar IN, Sy CB, van den Akker T, Kim D, Geyer JT, Chadburn A, et al. Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib. Pathobiology. 2023. doi:10.1159/000530429

BibTeX
@article{SahBandar2023,
  author = {SahBandar, Ivo N and Sy, Chandler B and van den Akker, Tayler and Kim, David and Geyer, Julia T and Chadburn, Amy and Cesarman, Ethel and Inghirami, Giorgio and Allan, John N and Siddiqui, Momin T and Ouseph, Madhu M},
  title = {Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib},
  journal = {Pathobiology},
  year = {2023},
  doi = {10.1159/000530429}
}
Kostenlos starten →